

## Financial Tear Sheet

### Corporate Profile

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. We maintain a deep commitment to the success of our customers, with comprehensive technical, clinical, and service support programs. IRIDEX is dedicated to a standard of excellence, offering superior technology for superior results. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 70 independent distributors into over 100 countries.

### Primary IR Contact

Lynn Lewis or Leigh Salvo

**Phone:** (415) 937-5404

**E-mail:** [investors@iridex.com](mailto:investors@iridex.com)

### Stock Performance

IRIX (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	<b>\$4.90</b>
Change (%)	▼ 0.01 (0.20%)
Volume	7,952
52 Week Low	\$4.23
Market Cap	\$66,611,286
Rolling EPS	-1.29
PE Ratio	N/A
Shares Outstanding	13,594,140
Data as of 11/16/18 3:57 p.m. ET	



### Recent Headlines & Events

11/01/18

IRIDEX Announces 2018 Third Quarter Financial Results and Raises Full Year 2018 Guidance

10/25/18

IRIDEX to Participate in Upcoming Investor Conferences

10/23/18

Leading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAO

There are currently no events scheduled.


Powered By **EDGAR Online**

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed

## Analyst Estimates / Ratings

Mean  
Recommendation:  
1.5



Unable to fulfill request.

## SEC Filings

Filing Date	Form
11/07/18	SC 13G
11/06/18	10-Q
11/01/18	8-K
10/16/18	4

## Corporate Governance

William M. Moore	President and CEO
Atabak Mokari	Chief Financial Officer and Vice President of Corporate Development
Timothy D. Buckley	Vice President, Marketing & North American Sales
George Marcellino	Vice President Clinical Affairs
Stacie Rodgers	Vice President of Human Resources

## Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	57	63.91	75.2	10,217,732
Mutual Fund	32	13.02	14.8	2,010,732
Insider *	10	16.69	13.6	1,851,018

\*Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Acuta Capital Partners, LLC	1,947,500	14.3	-52,500	09/30/18
Wasatch Advisors, Inc.	1,433,057	10.5	103,582	10/31/18
Paragon JV Partners, LLC	1,320,000	9.7	70,000	09/30/18
Stanley Manne Trust	1,072,215	7.9	0	04/16/18
BlueLine Partners, L.L.C.	982,742	7.2	-1,077,946	12/31/17
Moore (William M)	419,247	3.1	50,000	09/14/18
The Vanguard Group, Inc.	403,547	3.0	11,000	09/30/18
Renaissance Technologies LLC	335,500	2.5	14,100	09/30/18
Driehaus Capital Management, LLC	280,000	2.1	280,000	09/30/18
Perkins Capital Management, Inc.	227,950	1.7	156,000	09/30/18